Record Information |
---|
Version | 2.0 |
---|
Created at | 2005-11-16 15:48:42 UTC |
---|
Updated at | 2021-10-07 20:42:01 UTC |
---|
NP-MRD ID | NP0000614 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Nicotinic acid |
---|
Description | Nicotinic acid, also known as niacin or vitamin B3, is a water-soluble vitamin whose derivatives such as NADH, NAD, NAD+, and NADP play essential roles in energy metabolism in the living cell and DNA repair. The designation vitamin B3 also includes the amide form, nicotinamide or niacinamide. Severe lack of niacin causes the deficiency disease pellagra, whereas a mild deficiency slows down the metabolism decreasing cold tolerance. The recommended daily allowance of niacin is 2-12 mg a day for children, 14 mg a day for women, 16 mg a day for men, and 18 mg a day for pregnant or breast-feeding women. It is found in various animal and plant tissues and has pellagra-curative, vasodilating, and antilipemic properties. The liver can synthesize niacin from the essential amino acid tryptophan, but the synthesis is extremely slow and requires vitamin B6; 60 mg of tryptophan are required to make one milligram of niacin. Bacteria in the gut may also perform the conversion but are inefficient. |
---|
Structure | InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) |
---|
Synonyms | Value | Source |
---|
3-Carboxylpyridine | ChEBI | 3-Carboxypyridine | ChEBI | 3-Pyridinecarboxylic acid | ChEBI | 3-Pyridylcarboxylic acid | ChEBI | Acide nicotinique | ChEBI | Acido nicotinico | ChEBI | Acidum nicotinicum | ChEBI | Anti-pellagra vitamin | ChEBI | beta-Pyridinecarboxylic acid | ChEBI | m-Pyridinecarboxylic acid | ChEBI | Niacin | ChEBI | Niacor | ChEBI | Niaspan | ChEBI | Nicotinsaure | ChEBI | Nikotinsaeure | ChEBI | P.P. factor | ChEBI | Pellagra preventive factor | ChEBI | PP Factor | ChEBI | Pyridine-beta-carboxylic acid | ChEBI | Pyridine-carboxylique-3 | ChEBI | Vitamin b3 | ChEBI | 3-Pyridinecarboxylate | Generator | 3-Pyridylcarboxylate | Generator | b-Pyridinecarboxylate | Generator | b-Pyridinecarboxylic acid | Generator | beta-Pyridinecarboxylate | Generator | Β-pyridinecarboxylate | Generator | Β-pyridinecarboxylic acid | Generator | m-Pyridinecarboxylate | Generator | Pyridine-b-carboxylate | Generator | Pyridine-b-carboxylic acid | Generator | Pyridine-beta-carboxylate | Generator | Pyridine-β-carboxylate | Generator | Pyridine-β-carboxylic acid | Generator | Nicotinate | Generator | Akotin | HMDB | Apelagrin | HMDB | Daskil | HMDB | Efacin | HMDB | Enduracin | HMDB | Linic | HMDB | Niac | HMDB | Niacine | HMDB | Nicacid | HMDB | Nicamin | HMDB | Nicangin | HMDB | Nico-span | HMDB | Nicobid | HMDB | Nicocap | HMDB | Nicodelmine | HMDB | Nicolar | HMDB | Niconacid | HMDB | Nicosan 3 | HMDB | Nicotinipca | HMDB | Nicyl | HMDB | Nyclin | HMDB | Pellagrin | HMDB | Pelonin | HMDB | Slo-niacin | HMDB | Wampocap | HMDB | Aluminum salt, niacin | HMDB | Induracin | HMDB | Niacin cobalt (2+) salt | HMDB | Niacin iron (2+) salt | HMDB | Niacin lithium salt | HMDB | Niacin magnesium salt | HMDB | Niacin sodium salt | HMDB | Nico-400 | HMDB | Potassium salt, niacin | HMDB | Sodium salt, niacin | HMDB | Tosylate, niacin | HMDB | Nicotinate, lithium | HMDB | Hydrochloride, niacin | HMDB | Niacin aluminum salt | HMDB | Niacin calcium salt | HMDB | Niacin copper (2+) salt | HMDB | Niacin hydrochloride | HMDB | Niacin lithium salt, hemihydrate | HMDB | Nico400 | HMDB | Tartrate, niacin | HMDB | 3 Pyridinecarboxylic acid | HMDB | Lithium nicotinate | HMDB | Niacin ammonium salt | HMDB | Niacin manganese (2+) salt | HMDB | Niacin potassium salt | HMDB | Niacin tartrate | HMDB | Niacin tosylate | HMDB | Niacin zinc salt | HMDB | Nico 400 | HMDB |
|
---|
Chemical Formula | C6H5NO2 |
---|
Average Mass | 123.1094 Da |
---|
Monoisotopic Mass | 123.03203 Da |
---|
IUPAC Name | pyridine-3-carboxylic acid |
---|
Traditional Name | niacin |
---|
CAS Registry Number | 59-67-6 |
---|
SMILES | OC(=O)C1=CN=CC=C1 |
---|
InChI Identifier | InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) |
---|
InChI Key | PVNIIMVLHYAWGP-UHFFFAOYSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Species Where Detected | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyridinecarboxylic acids. Pyridinecarboxylic acids are compounds containing a pyridine ring bearing a carboxylic acid group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Pyridinecarboxylic acids and derivatives |
---|
Direct Parent | Pyridinecarboxylic acids |
---|
Alternative Parents | |
---|
Substituents | - Pyridine carboxylic acid
- Heteroaromatic compound
- Azacycle
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | 236.6 °C | Not Available | Boiling Point | 292.47 °C. @ 760.00 mm Hg (est) | The Good Scents Company Information System | Water Solubility | 18 mg/mL | Not Available | LogP | 0.36 | Sangster, J. (1993). LOGKOW- a Databank of Evaluated Octanol-Water Partition Coefficients. Sangster Research Laboratories, Montreal. |
|
---|
Predicted Properties | |
---|
General References | - Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003 Mar;9(3):352-5. Epub 2003 Feb 3. [PubMed:12563315 ]
- Dastur DK, Santhadevi N, Quadros EV, Avari FC, Wadia NH, Desai MN, Bharucha EP: The B-vitamins in malnutrition with alcoholism. A model of intervitamin relationships. Br J Nutr. 1976 Sep;36(2):143-59. [PubMed:182198 ]
- Salvi A, Carrupt PA, Mayer JM, Testa B: Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid. Drug Metab Dispos. 1997 Apr;25(4):395-8. [PubMed:9107536 ]
- Hertle H, Kiese M, Renner G: Absorption in rats, dogs, pigs, and humans of nicotinic acid after oral administration of phosphatidyl inositol pentanicotinate hydrochloride (PIN). Arzneimittelforschung. 1979;29(1):114-6. [PubMed:582105 ]
- Zarzycki PK, Kowalski P, Nowakowska J, Lamparczyk H: High-performance liquid chromatographic and capillary electrophoretic determination of free nicotinic acid in human plasma and separation of its metabolites by capillary electrophoresis. J Chromatogr A. 1995 Aug 11;709(1):203-8. [PubMed:7581845 ]
- Hengen N, Seiberth V, Hengen M: High-performance liquid-chromatographic determination of free nicotinic acid and its metabolite, nicotinuric acid, in plasma and urine. Clin Chem. 1978 Oct;24(10):1740-3. [PubMed:699281 ]
- Santos RD: [Pharmacology of niacin or nicotinic acid]. Arq Bras Cardiol. 2005 Oct;85 Suppl 5:17-9. Epub 2006 Jan 2. [PubMed:16400392 ]
- Mrochek JE, Jolley RL, Young DS, Turner WJ: Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem. 1976 Nov;22(11):1821-7. [PubMed:135660 ]
- Pike NB: Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest. 2005 Dec;115(12):3400-3. [PubMed:16322787 ]
- Kobayashi M, Shimizu S: [Nicotinic acid and nicotinamide]. Nihon Rinsho. 1999 Oct;57(10):2211-7. [PubMed:10540864 ]
- Sutherland WH, Larking PW, Nye ER: Modification of nicotinic acid and prostaglandin E1 antilipolytic action in vitro. Atherosclerosis. 1976 Oct;25(1):45-53. [PubMed:186078 ]
- Stratford MR, Dennis MF, Hoskin P, Phillips H, Hodgkiss RJ, Rojas A: Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Br J Cancer. 1996 Jul;74(1):16-21. [PubMed:8679452 ]
- Angelin B, Einarsson K, Leijd B: Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest. 1979 Jun;9(3):185-90. [PubMed:113218 ]
- Patterson MC, Di Bisceglie AM, Higgins JJ, Abel RB, Schiffmann R, Parker CC, Argoff CE, Grewal RP, Yu K, Pentchev PG, et al.: The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology. 1993 Jan;43(1):61-4. [PubMed:8423912 ]
- Muller B, Kasper M, Surber C, Imanidis G: Permeation, metabolism and site of action concentration of nicotinic acid derivatives in human skin. Correlation with topical pharmacological effect. Eur J Pharm Sci. 2003 Oct;20(2):181-95. [PubMed:14550884 ]
- Chekalina SI, Guseva LI, Bardyechev MS: [Use of nicotinic acid and midocalm for correcting blood coagulation in patients with radiation edema of the extremities]. Med Radiol (Mosk). 1985 Aug;30(8):28-30. [PubMed:4033386 ]
- Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V: Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by slc5a8, a member of the Na/glucose co-transporter gene family. Biochem J. 2005 May 15;388(Pt 1):309-16. [PubMed:15651982 ]
|
---|